5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: A randomized phase 3 trial with a primary pain endpoint
    Journal Article

    Basch, E. M.; Scholz, M.; de Bono, J. S.; Vogelzang, N.; de Souza, P.; Marx, G.; Vaishampayan, U.; George, S.; Schwarz, J. K.; Antonarakis, E. S.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • Phase III Trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
    Journal Article

    Gulley, J. L.; Borre, M.; Vogelzang, N. J.; Ng, S.; Agarwal, N.; Parker, C. C.; Pook, D. W.; Rathenborg, P.; Flaig, T. W.; Carles, J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study
    Journal Article

    Armstrong, A. J.; Halabi, S.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Anand, M.; Rothwell, C. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Lessons learned from exceptional responders
    Review

    Iyer, G.; Rosenberg, J. E.
    Expert Review of Precision Medicine and Drug Development (2019)

    Fulltext@MSK | Save
  • Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: A phase 1 dose escalation/randomised phase 2a trial
    Journal Article

    Morris, M. J.; Loriot, Y.; Sweeney, C. J.; Fizazi, K.; Ryan, C. J.; Shevrin, D. H.; Antonarakis, E. S.; Pandit-Taskar, N.; Deandreis, D.; Jacene, H. A.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Journal Article

    Shah, A. Y.; Kotecha, R. R.; Lemke, E. A.; Chandramohan, A.; Chaim, J. L.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations
    Journal Article

    Voss, M. H.; Hierro, C.; Heist, R. S.; Cleary, J. M.; Meric-Bernstam, F.; Tabernero, J.; Janku, F.; Gandhi, L.; Iafrate, A. J.; Borger, D. R.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Overall responses and survival in RCC on pegilodecakin with anti-PD-1
    Meeting Abstract

    Naing, A.; Infante, J. R.; Wong, D. J.; Korn, W. M.; Aljumaily, R.; Papadopoulos, K. P.; Autio, K. A.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: Clinical trial evidence and experience
    Review

    Crist, M.; Iyer, G.; Hsu, M.; Huang, W. C.; Balar, A. V.
    Therapeutic Advances in Urology (2019)

    Fulltext@MSK | Save
  • Harnessing clinical sequencing data for survival stratification of patients with metastatic lung adenocarcinomas
    Journal Article

    Shen, R.; Martin, A.; Ni, A.; Hellmann, M.; Arbour, K. C.; Jordan, E.; Arora, A.; Ptashkin, R.; Zehir, A.; Kris, M. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save